Fatma Radhi, MD
Neurology · Manhattan, KSNPI 1396848461
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,129 and has fallen 89.3% since, to $120 in 2025.
Across 151 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$360
- Livanova USA, Inc.$225
- EMD Serono, Inc.$223
- AstraZeneca$157
- Supernus Pharmaceuticals, Inc.$139
- Jazz Pharmaceuticals Inc.$118
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$642%
- Food & beverage$2,48794%
- Education$1024%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 30 | $360 |
| Livanova USA, Inc. | 12 | $225 |
| EMD Serono, Inc. | 6 | $223 |
| AstraZeneca | 13 | $157 |
| Supernus Pharmaceuticals, Inc. | 13 | $139 |
| Jazz Pharmaceuticals Inc. | 5 | $118 |
| UCB, Inc. | 6 | $116 |
| Azurity Pharmaceuticals, Inc. | 1 | $108 |
| Amgen | 5 | $103 |
| Biogen | 6 | $98 |
| Lilly USA, LLC | 5 | $96 |
| Novartis | 5 | $94 |
| Acadia Pharmaceuticals Inc | 5 | $90 |
| Acorda Therapeutics, Inc | 4 | $86 |
| Harmony Biosciences LLC | 3 | $84 |
| Sanofi | 5 | $83 |
| Lundbeck LLC | 4 | $83 |
| AbbVie(2 entities) | 4 | $66 |
| Biohaven Pharmaceuticals, Inc. | 3 | $56 |
| Adamas Pharmaceuticals, Inc. | 2 | $42 |
| Kyowa Kirin, Inc. | 2 | $36 |
| SK Life Science, Inc. | 2 | $35 |
| Genentech USA, Inc. | 2 | $30 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| GRT US Holding, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Horizant$108
How this compares
$2,653 in reported general payments places this provider in the 60th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BetaseronInterferon Beta-1b | 25 | $250,266 |
| CopaxoneGlatiramer Acetate | 11 | $75,458 |
| NuplazidPimavanserin Tartrate | 13 | $60,067 |
| BriviactBrivaracetam | 17 | $36,916 |
| UbrelvyUbrogepant | 19 | $19,154 |
| Glatiramer Acetate | 11 | $15,216 |
| XcopriCenobamate | 11 | $12,771 |
| Oxcarbazepine | 46 | $11,576 |
| Topiramate ErTopiramate | 21 | $8,889 |
| Lacosamide | 17 | $8,451 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,095 |
| FingolimodFingolimod Hcl | 15 | $5,999 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 217 | $5,067 |
| Ropinirole ErRopinirole Hcl | 27 | $4,308 |
| Memantine Hcl | 154 | $3,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $360 | $75,45811 claims |
| Acadia Pharmaceuticals IncNuplazid | $90 | $60,06713 claims |
| UCB, Inc.Briviact | $116 | $36,91617 claims |
| AbbVieUbrelvy | $66 | $19,15419 claims |
| SK Life Science, Inc.Xcopri | $35 | $12,77111 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $17 | $52120 claims |
| Upsher-smith Laboratories LLCTopiramate | $18 | $32937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 131 neurology providers in Kansas.
Other neurology in Manhattan
- Nanda KumarManhattan$11K
- Ivan OsorioKansas City$101.7M
- Jeffrey KaplanLenexa$1.9M
- Rajesh PahwaKansas City$889K
- Sheetal MalikTopeka$137K
- Richard DubinskyKansas City$122K
- Barbara Jean OttleyHays$116K
- Jeffrey BurnsKansas City$115K
- Douglas DavisSalina$100K
- Amanda ThuringerKansas City$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.